PMC8784412_01
Abdominal axial (A) and coronal (B) non-enhanced CT images show a large well-defined rounded tumor, with a heterogeneous appearance in the cervix and demonstrating mass effect in adjacent structures and preserving interface with the bladder wall and rectum. (C) Axial non-enhanced CT, three months after surgery shows a heterogeneous abdominal tumor that compresses and displaces adjacent structures.
fmed-08-819141-g0001.jpg
PMC8784412_01_fmed-08-819141-g0001.jpg
F1
It was reported as UASO with heterologous elements of grade 2 chondrosarcoma (Figure 1). Abdominopelvic computed tomography was performed identifying a tumor adhered to the pelvic and abdominal cavity with dimensions of 30 x 25 cm (Figure 1C), with multiples peritoneal implants, for which she was operated on again.
Macroscopic surgical specimen. (A) External surface of the posterior aspect of the uterus, a lesion that completely distorts the architecture of the cervix can be seen, the lesion has a pseudo-encapsulated fleshy appearance with some areas of irregular myxoid appearance. (B) Uterus, cut surface, with tumor originating in the lower uterine segment, with protrusion through the endocervical canal and expansion of the exocervix, showing the involvement of the endocervical wall.
fmed-08-819141-g0002.jpg
PMC8784412_01_fmed-08-819141-g0002.jpg
F2
A computed tomography scan was performed that showed a neoformative process at the cervical level (Figures 2A,B).
Histology of the tumor. (A,B) A mixed malignant neoplasm made up of cartilaginous areas that alternate with areas of paucicellular spindle malignant cells is observed, within which tubular and ectatic glandular structures can be seen. (C) Formation of "leaf-shaped" structures. (D) Malignant high-grade spindle cell component. (E) Glands with a "benign" endometrial appearance, surrounded by packed malignant stromal cells (cambium layer). (F) Extensive areas with malignant chondroid differentiation.
fmed-08-819141-g0003.jpg
PMC8784412_01_fmed-08-819141-g0003.jpg
F3
Tumor size: 9 cm) (Figure 3).
Immunohistochemistry. (A) CD10. (B) p53. (C) Beta-catenina. (D) hTERT. (E) PMS2. (F) S-100.
fmed-08-819141-g0004.jpg
PMC8784412_01_fmed-08-819141-g0004.jpg
F4
Immunohistochemistry was positive for CD10, estrogen and progesterone receptors, p53, cyclin D1, WT1, PMS2, b-catenin an S100, it last found chondrosarcoma component (Figure 4).